Russia’s war may change how Europe talks about trauma, and about psychedelic therapy.
Editor’s note: This is an opinion piece. The author is a co-founder and Secretary General of PsychedelicsEUROPE, which organized the SCALE conference described below and is one of three organizations behind the proposals in the final section. Magdalena Kaspryszyn and Tais Poda, who are quoted and credited as contributors, represent the other two. The views expressed are the author’s own.
For the past decade, psychedelic advocacy in the United States has been shaped by therapists, scientists and activists, and increasingly by military veterans. PTSD became one of the most persuasive arguments in the American debate over psychedelic medicine and access. That was not an accident. American military culture, and the country’s relationship with its veterans, have no close equivalent in continental Europe.
Russia’s war against Ukraine may change that. The mental-health crisis it has produced is first a Ukrainian tragedy, affecting soldiers, veterans, families and civilians. Its consequences will not stop at Ukraine’s borders. EU member states, particularly those on the eastern flank, will absorb part of the war’s human and social fallout. The question is no longer whether mental health belongs in Ukraine’s reconstruction. It is whether Europe is prepared to treat it as part of its own resilience.
For three years, PsychedelicsEUROPE has argued that mental health must be an integral part of Ukraine’s reconstruction. There is now an opening for experts, institutions and policymakers from Ukraine, the EU and the United States to work together on a European response to trauma, rather than treating the consequences of war one patient at a time.
The Scale of the Crisis
Ukraine has lived with armed conflict since 2014 and with full-scale invasion since February 2022. PTSD and other trauma-related disorders affect soldiers and civilians alike, with the highest rates among people directly exposed to combat, occupation and displacement. In an online survey of 5,523 adults in Ukraine conducted in mid-2025, 8.6% screened positive for probable PTSD. In a clinician-assessed study of 590 active-duty Ukrainian military personnel treated in hospitals and rehabilitation centers in Dnipro, Ternopil and Kyiv, published in Acta Psychiatrica Scandinavica, 45.9% met criteria for PTSD and a further 21.5% for complex PTSD.
The wider population is under strain as well. In a 2025 health needs assessment, the World Health Organization found that more than 70% of Ukrainian adults surveyed had experienced symptoms of anxiety, depression or severe stress in the previous year. Only one in five sought professional help. Ukraine’s health system will be carrying this burden long after the fighting stops.
This is where psychedelic-assisted therapy could make a difference. It is not a miracle cure and should not be presented as one. Clinical trials of MDMA- and psilocybin-assisted therapy, along with established clinical experience with ketamine, suggest a different approach may help some people with severe or treatment-resistant trauma. The evidence is not settled. In 2024 the US Food and Drug Administration declined to approve MDMA-assisted therapy for PTSD and asked for a further trial. If rigorous research, appropriate regulation and closely supervised medical practice can turn early results into real-world care, psychedelic therapies could become part of Ukraine’s long-term mental-health response, and a model for how Europe treats the psychological consequences of war.
The Frontline Cannot Wait
The need is not evenly distributed. People living and fighting closest to the front face repeated exposure to violence, displacement, loss and uncertainty that conventional statistics struggle to capture. Frontline regions are also absorbing large numbers of people internally displaced from occupied territories.

PsychedelicsEUROPE regularly visits the Dnipropetrovsk region in southeastern Ukraine, where Dnipro is the last major city before the front line. Through these visits we have built close working relationships with regional health officials, including Professor Svitlana Moroz, MD, PhD, DSc, chief executive of the Dnipropetrovsk Multidisciplinary Clinical Psychiatric Care Hospital and a representative on the Dnipropetrovsk Regional Council.
“As a doctor, I believe in every evidence-based method that can help our citizens overcome the psychological consequences of war. Ukraine faces an enormous challenge in treating PTSD, and we must be open to new approaches, including psychedelic-assisted therapies. Even if a treatment helps five percent of patients, that matters; if it helps ten percent, it is an excellent result. We are already preparing our staff to provide ketamine-assisted therapy, and I hope that psychedelic-assisted treatment will become another important option for patients in Ukraine who need it most.”
The challenge is not only to show that a treatment works in a controlled clinical trial. It is to find out whether evidence-based psychedelic therapies can be integrated into a health system facing extraordinary need, while keeping the clinical safeguards, trained professionals and regulatory standards these treatments require.
From Ukraine’s Trauma to Europe’s Response
Europe’s response to the war cannot be limited to weapons, humanitarian aid and rebuilding physical infrastructure. If Ukraine is to recover, its mental-health system has to recover with it. And if Europe wants to be resilient in a period of overlapping crises, it has a direct interest in that process.
That will require coordinating work at the EU level with work in member states, especially in Central and Eastern Europe, such as Czechia and Poland, and connecting both to developments in Ukraine. Magdalena Kaspryszyn, co-founder and CEO of the HoloMind Foundation, put it this way:
“Warsaw, a city that experienced the outbreak of the Second World War and witnessed the devastating, intergenerational consequences of war trauma, once again became a place of refuge when over a million Ukrainians fled across the Polish border in 2022, an experience that gave rise to the HoloMind Foundation and our commitment to supporting those affected by the war. However, we have come to understand that the mental health consequences extend far beyond the Ukrainian population, affecting Polish citizens as well, through direct exposure to the war, the emotional burden of supporting refugees, and the growing impact of disinformation on social resilience. By joining forces with Czechia, whose more developed regulatory framework and experience can complement Poland’s strong pool of mental health professionals ready to contribute, and with Ukraine’s direct understanding of the needs on the ground, we can build a practical, cross-border system of support that addresses not only Ukraine’s urgent needs but also the long-term mental health and resilience of our entire region.”
Czechia offers one of the clearest examples of what that coordination can look like. During its 2022 Presidency of the Council of the European Union, it helped put mental health back on the European agenda, and it was among the first countries to position PTSD and mental healthcare as essential parts of Ukraine’s recovery. It is home to active psychedelic research, an evidence-based drug policy and a growing network of clinics offering ketamine-assisted therapy. In 2025, the Czech Parliament approved legislation allowing the medical use of psilocybin in specialized healthcare facilities. The law took effect on January 1, 2026. Treatment will begin once reimbursement and funding rules are settled. No start date has been announced. My own estimate is mid-2027.
On October 13, 2026, PsychedelicsEUROPE and the Psyres Foundation for Psychedelic Research held the third edition of SCALE at Prague Castle, a conference on the medical use of psychedelics that brought together clinicians, researchers, veterans, advocates and policymakers from the EU, the United States and Ukraine to discuss regulation, reimbursement, patient access and PTSD.
A side event, Frontline, held at the Czech National Institute of Mental Health the day before, focused on PTSD as a question of security, social resilience and long-term recovery, as well as health care. Tais Poda, a co-founder of the Ukrainian Psychedelic Research Association (UPRA), describes what Ukraine has learned:
“What Ukraine has learned the hard way is that people’s resilience is not a soft issue. It is part of national security, just like air defense. Russia understands this. That is why it goes after our sleep, our trust and our hope, not only our power plants. And for Poland and Czechia, right next door and already dealing with drones, sabotage and disinformation, this is very real. Our experience points to a few practical steps for partners. Treat resilience as part of defense and put real money behind it. Teach psychological first aid the way you teach CPR. Prepare your armies for the psychological cost of war. And work with Ukraine as an expert partner. Psychedelic-assisted therapy is part of this picture. It will not replace primary care, but new tools are exactly what a challenge of this scale demands, with soldiers, veterans and civilians in need of help in numbers no conventional system was built for. Ukraine is now close to allowing psychedelic research, which is prohibited today. That will let us build the knowledge and data we need for evidence-based care, with particular attention to ethics.”
What Comes Next
Coming out of the conference, PsychedelicsEUROPE, the HoloMind Foundation and UPRA are calling for a regional initiative linking Czechia, Poland and Ukraine on PTSD care and psychological resilience. The proposed Central and Eastern Europe (CEE) Commission on PTSD would connect researchers and clinicians, share expertise, and coordinate evidence-based engagement with national authorities and EU institutions, with the aim of turning that cooperation into better care for people affected by war and trauma.
At the national level, a second proposal from SCALE 2026 is an Association of Providers of Psychedelic-Assisted Therapy in Czechia. The number of clinical providers is growing, but they have no collective organization and no shared voice in discussions with government, regulators and public health insurers. An association could support implementation of the Czech model, help make it a lasting reference point for other countries, and represent providers before EU institutions in Brussels.
Funding will decide how much of this becomes practical care. EU financial instruments should reflect the region’s geopolitical realities and recognize the connection between mental health, societal resilience and security. Specifically, Horizon Europe and other relevant programs should fund projects that link PTSD research and care with psychedelic-assisted therapy, cross-border research and clinical training.

